argenx Announces Results of Annual General Meeting of Shareholders

Rhea-AI Summary

argenx SE (Euronext & Nasdaq: ARGX) held its Annual General Meeting of shareholders on May 27, 2025, with 91.1% of the company's share capital represented. Most agenda items received majority approval, except for the remuneration policy (agenda item 5) which received 73.0% approval, falling short of the required 75% threshold.

Key approved resolutions included: the 2024 remuneration report (76.7% in favor), 2024 annual report and accounts (99.9% approval), re-appointment of Anthony Rosenberg as non-executive director (93.6% approval), and authorization for the Board to issue shares up to 10% of outstanding share capital (99.4% approval).

News Market Reaction – ARGX

+0.82%

+0.82% Session move

In the trading session that priced this news, ARGX gained 0.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

May 28, 2025 – 10:01 PM CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025.

91.1% of the Company’s share capital was represented at the Annual General Meeting.

All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0% majority where a 75% majority was required.

As part of the approved resolutions:

• The Company’s 2024 remuneration report received a 76.7% majority in favor advisory vote;
• The Company's annual report and annual accounts for the financial year ending December 31, 2024 were approved with a 99.9% majority;
• Anthony Rosenberg has been re-appointed as non-executive director to the Board of Directors for a term of two years with a 93.6% majority; and
• The Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights with a 99.4% majority.

The voting result and all documents relating to the shareholders’ meeting will be available on the argenx
website at www.argenx.com/investors/shareholder-meetings.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

For further information, please contact:  

Media:

Ben Petok
Bpetok@argenx.com

Investors:

Alexandra Roy (US) 
aroy@argenx.com 

FAQ

What were the key results of ARGX's 2025 Annual General Meeting?

Most agenda items were approved, except for the remuneration policy. Key approvals included the 2024 remuneration report (76.7%), annual report (99.9%), re-appointment of Anthony Rosenberg (93.6%), and authorization to issue shares up to 10% of capital (99.4%).

Why did ARGX's remuneration policy fail to pass at the 2025 AGM?

The remuneration policy received 73.0% approval but failed to pass as it required a minimum 75% majority vote for adoption.

Who was re-appointed to ARGX's Board of Directors in the 2025 AGM?

Anthony Rosenberg was re-appointed as non-executive director to the Board of Directors for a term of two years with a 93.6% majority approval.

What share issuance authority was granted to ARGX's Board in the 2025 AGM?

The Board was authorized to issue shares up to 10% of outstanding share capital for a period of 18 months, with the ability to limit or exclude statutory pre-emptive rights, approved by 99.4% majority.